SAB Biotherapeutics, Inc. — Director's Dealing 2021

Nov 16, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: SAB Biotherapeutics, Inc. (SABS)
CIK: 0001833214
Period of Report: 2021-10-18

Reporting Person: Beyer Russell P (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-10-18	Common Stock	A	2475	$10.10	Acquired	2475	Direct
2021-09-28	Common Stock	A	149	$10.08	Acquired	149	Indirect
2021-10-25	Common Stock	A	129	$7.78	Acquired	278	Indirect
2021-10-26	Common Stock	S	278	$7.90	Disposed	0	Indirect
2021-09-28	Common Stock	A	5	$10.07	Acquired	5	Indirect
2021-09-29	Common Stock	A	10	$10.08	Acquired	15	Indirect

Footnotes

F1: This transaction occurred prior to the business combination pursuant to the Agreement and Plan of Merger, dated June 21, 2021 and as amended August 12, 2021, by and among Big Cypress Acquisition Corp., Big Cypress Merger Sub Inc., and SAB Biotherapeutics, Inc. ("Issuer"). The reporting person's obligation to disclose this transaction occurred upon the consummation of the business combination.

F2: The sale of Issuer common stock by the reporting person's spouse reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 278 shares, with the purchase of 278 shares of Issuer's common stock as also reported herein. The reporting person has paid to Issuer, upon settlement of the sale, $15.48, representing the full amount of the profit realized in connection with the short-swing transaction.